Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of$ 0.54. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.37%. A quarter ago, it was expected that this company would post a loss of$ 0.57 per share when it actually produced a loss of $0.4, delivering a surprise of +29.82%.Over the last four quarters, the company ...